title: A longer acting rFVIII, safe and effective.
abstract: In this issue of Blood, Mahlangu et al describe a well-designed and executed phase 3 multicenter study of a recombinant factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hemophilia A.
authors.affiliation: WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE.
authors.forename: Jeanne M
authors.initials: JM
authors.lastname: Lusher
mesh_terms: D005169:Factor VIII / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000627:therapeutic use*; D008297:Male; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins; C587014:factor VIII-Fc fusion protein; D005169:Factor VIII